اعلان هااااااااااااااام


Translate

Horizon Pharma Receives Marketing Authorization for DUEXIS(R) From the United Kingdom Medicines and Healthcare Products Regulatory Agency (Horizon Pharma Inc)

Thursday, March 7, 2013

WN.com - Health News
Latest headlines from WN Network
Horizon Pharma Receives Marketing Authorization for DUEXIS(R) From the United Kingdom Medicines and Healthcare Products Regulatory Agency (Horizon Pharma Inc)
Mar 7th 2013, 13:14

(Source: Horizon Pharma Inc) DEERFIELD, IL -- (Marketwire) -- 03/07/13 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for DUEXIS® (ibuprofen/famotidine) for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who require regular treatment with high dose ibuprofen administered three times a day and who are at risk of developing non-steroidal anti-inflammatory drug (NSAID) associated gastric and/or duodenal ulcers. Horizon is seeking to license rights to DUEXIS in Europe to one or more commercial partners....
You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

0 Responses to Horizon Pharma Receives Marketing Authorization for DUEXIS(R) From the United Kingdom Medicines and Healthcare Products Regulatory Agency (Horizon Pharma Inc)

Post a Comment